股票行情快报：祥生医疗（688358）2月3日主力资金净卖出19.17万元

Core Viewpoint - Xiangsheng Medical (688358) has shown a mixed financial performance with a decline in revenue and net profit for the first three quarters of 2025, while the third quarter showed a significant increase in net profit compared to the previous year [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 343 million yuan, a year-on-year decrease of 5.27% [2]. - The net profit attributable to the parent company was 93.92 million yuan, down 4.56% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 86.97 million yuan, a decrease of 2.69% year-on-year [2]. - In the third quarter of 2025, the company's single-quarter main revenue was 107 million yuan, a decline of 6.68% year-on-year [2]. - The single-quarter net profit attributable to the parent company was 24.22 million yuan, an increase of 41.95% year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was 23.14 million yuan, an increase of 53.63% year-on-year [2]. - The company's debt ratio was 11.24%, with investment income of 3.01 million yuan and financial expenses of -16.53 million yuan [2]. - The gross profit margin stood at 59.82% [2]. Stock Performance - As of February 3, 2026, Xiangsheng Medical's stock closed at 36.17 yuan, up 3.64% with a turnover rate of 1.32% and a trading volume of 14,800 hands, amounting to a transaction value of 53.04 million yuan [1]. - On February 3, the net outflow of main funds was 191,700 yuan, accounting for 0.36% of the total transaction value, while the net outflow of speculative funds was 5.54 million yuan, accounting for 10.44% of the total transaction value [1]. - Retail investors saw a net inflow of 5.73 million yuan, representing 10.8% of the total transaction value [1]. Analyst Ratings - In the last 90 days, three institutions have given buy ratings for Xiangsheng Medical [3].